comparemela.com

Latest Breaking News On - Healthcare royalty - Page 8 : comparemela.com

ADC Therapeutics SA (NYSE:ADCT) Q2 2023 Earnings Call Transcript

ADC Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Updates

2Q 2023 ZYNLONTA®1 net sales increased 11% year-over-year; Implemented new go-to-market strategy during the quarter to support growth Operating expenses decreased 20%2 year-over-year due to portfolio prioritization and organizational efficiencies Pipeline advancing with initial data readouts from the clinical trials of LOTIS-7, ADCT-601 targeting AXL and ADCT-901 targeting KAAG1 expected in 2024 Company to host conference call today at 8:30 a.m. EDT LAUSANNE, Switzerland, Aug. 08, 2023 (GLOBE NE

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.